A PHASE II TRIAL OF WEEKLY DOCETAXEL COMBINED WITH CARBOPLATIN AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED NON-SMALL-CELL LUNG CANCER

被引：0
|
作者：
Nong, X. [1 ]
Zhang, X. [1 ]
Xiong, J. [2 ]
Fang, W. [1 ]
Zhang, L. [2 ]
Zhong, L. [3 ]
Chen, J. [1 ]
Yu, F. [2 ]
Qian, J. [1 ]
Deng, J. [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
[2] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang, Peoples R China
[3] Beijing Merck Pharmaceut Consulting Ltd, Oncol Business Unit, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [1] Phase II trial of weekly docetaxel and carboplatin as first line chemotherapy in advanced or metastatic non small cell lung cancer (NSCLC).
    Chahine, GY
    Nasr, FL
    Kattan, JG
    Farhat, FS
    El Seoudi, ME
    Bachour, M
    Moukadem, WT
    Younes, FC
    Ghosn, MG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
  • [2] A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced non-small cell lung cancer
    Jiang, Haiping
    Zhang, Xiaochen
    Chen, Jing
    Zhang, Ling
    Xiong, Jianping
    Zhong, Lin
    Yu, Feng
    Qian, Jiong
    Yu, Lanfang
    Wang, Xiaoting
    Shi, Genming
    Deng, Jing
    Xu, Nong
    [J]. JOURNAL OF THORACIC DISEASE, 2014, 6 (02) : 79 - 85
  • [3] A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer
    Kiyoshi Mori
    Hiroyuki Kobayashi
    Yukari Kamiyama
    Yasuhiko Kano
    Tetsuro Kodama
    [J]. Cancer Chemotherapy and Pharmacology, 2009, 64 : 73 - 78
  • [4] A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer
    Mori, Kiyoshi
    Kobayashi, Hiroyuki
    Kamiyama, Yukari
    Kano, Yasuhiko
    Kodama, Tetsuro
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 73 - 78
  • [5] Phase II trial of a combination of weekly docetaxel and four-weekly carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC)
    Ozguroglu, Mustafa
    Evrensel, Turkkan
    Er, Ozlem
    Turna, Hande
    Yanmaz, Teoman
    Yildiz, Ozcan
    Mandel, Nil
    Serdengecti, Suheyla
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 225 - 225
  • [6] Phase I/II trial of docetaxel (D) and Carboplatin (CBDCA) as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Giannakakis, T
    Papadouris, S
    Kourousis, C
    Kalbakis, NK
    Tzianni, V
    Lidaki, E
    Androulakis, N
    Souklakos, J
    Sarra, E
    Georgoulias, V
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 94 - 94
  • [7] A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer
    Mori, Kiyoshi
    Kamiyama, Yukari
    Kasai, Hisashi
    Kodama, Tetsuro
    [J]. CHEMOTHERAPY, 2012, 58 (01): : 78 - 83
  • [8] Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
    Kim, Hyeong Su
    Kim, Jung Han
    Kim, Byounghoon
    Choi, Hyun Chang
    Kwon, Jung Hye
    Choi, Dae Ro
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1591 - 1597
  • [9] Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
    Hyeong Su Kim
    Jung Han Kim
    Byounghoon Kim
    Hyun Chang Choi
    Jung Hye Kwon
    Dae Ro Choi
    [J]. Cancer Chemotherapy and Pharmacology, 2013, 71 : 1591 - 1597
  • [10] Phase I/II Trial of Docetaxel and Carboplatin as a First-Line Therapy in Patients with Stage IV Non-Small-Cell Lung Cancer
    Kensuke Kataoka
    Ryujiro Suzuki
    Hiroyuki Taniguchi
    Yasunobu Noda
    Joe Shindoh
    Syuichi Matsumoto
    Yoshiaki Watanabe
    Kousuke Honda
    Kiyoshi Suzuki
    Kenji Baba
    Kazuyoshi Imaizumi
    Hiroaki Kume
    Yoshinori Hasegawa
    Kenzo Takagi
    [J]. Lung, 2006, 184 : 133 - 139
12345